Pfizer Ltd
Pfizer Ltd is engaged in manufacturing, marketing, trading and export of pharmaceutical products. It manufactures products through its own facility and also has various independent contract/ third party manufacturers based across the country and sells its products through independent distributors primarily in India.[1]
It is the 3rd largest multinational pharmaceutical company in India.[2]
- Market Cap ₹ 22,694 Cr.
- Current Price ₹ 4,961
- High / Low ₹ 6,453 / 3,950
- Stock P/E 148
- Book Value ₹ 302
- Dividend Yield 0.69 %
- ROCE 27.2 %
- ROE 19.8 %
- Face Value ₹ 10.0
Pros
- Company is almost debt free.
- Company has been maintaining a healthy dividend payout of 33.2%
Cons
- Stock is trading at 16.5 times its book value
- Earnings include an other income of Rs.512 Cr.
- Working capital days have increased from 60.8 days to 135 days
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Sector: Pharmaceuticals Industry: Pharmaceuticals - Multinational
Part of BSE 400 MidSmallCap Index BSE 250 SmallCap Index BSE 500 BSE Healthcare Nifty 500
Quarterly Results
Consolidated Figures in Rs. Crores / View Standalone
Operating Profit |
OPM % |
Interest |
Depreciation |
Profit before tax |
Tax % |
EPS in Rs |
Raw PDF |
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
Nov 2006 | Nov 2007 | Nov 2008 | |
---|---|---|---|
664 | 676 | 678 | |
537 | 815 | 760 | |
Operating Profit | 127 | -139 | -82 |
OPM % | 19% | -21% | -12% |
48 | 600 | 512 | |
Interest | 0 | 0 | 0 |
Depreciation | 13 | 10 | 11 |
Profit before tax | 163 | 451 | 419 |
Tax % | 35% | 25% | 29% |
106 | 340 | 300 | |
EPS in Rs | 35.64 | 113.94 | 100.39 |
Dividend Payout % | 63% | 24% | 12% |
Compounded Sales Growth | |
---|---|
10 Years: | % |
5 Years: | % |
3 Years: | % |
TTM: | 0% |
Compounded Profit Growth | |
---|---|
10 Years: | % |
5 Years: | % |
3 Years: | % |
TTM: | 6% |
Stock Price CAGR | |
---|---|
10 Years: | 9% |
5 Years: | 5% |
3 Years: | 1% |
1 Year: | 19% |
Return on Equity | |
---|---|
10 Years: | % |
5 Years: | % |
3 Years: | % |
Last Year: | 20% |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
Nov 2006 | Nov 2007 | Nov 2008 | |
---|---|---|---|
Equity Capital | 30 | 30 | 30 |
Reserves | 376 | 620 | 871 |
0 | 0 | 0 | |
240 | 218 | 197 | |
Total Liabilities | 646 | 867 | 1,098 |
65 | 60 | 51 | |
CWIP | 2 | 10 | 32 |
Investments | 0 | 0 | 0 |
579 | 797 | 1,014 | |
Total Assets | 646 | 867 | 1,098 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
Nov 2006 | Nov 2007 | Nov 2008 | |
---|---|---|---|
123 | 17 | 238 | |
7 | 232 | -79 | |
-34 | -76 | -95 | |
Net Cash Flow | 97 | 173 | 64 |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
Nov 2006 | Nov 2007 | Nov 2008 | |
---|---|---|---|
Debtor Days | 38 | 33 | 32 |
Inventory Days | 160 | 149 | 190 |
Days Payable | 208 | 144 | 164 |
Cash Conversion Cycle | -10 | 39 | 58 |
Working Capital Days | 2 | 45 | 135 |
ROCE % | 37% | 27% |
Documents
Announcements
-
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
19h - Certificate under Regulation 74(5) for Q4 2024.
- Closure of Trading Window 30 Dec
- Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate 17 Dec
- Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate 11 Dec 2024
- Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate 3 Dec 2024
Annual reports
-
Financial Year 2024
from bse
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from nse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
-
Financial Year 2012
from nse
Concalls
-
Aug 2020TranscriptPPT
-
May 2017TranscriptPPT
-
Feb 2017TranscriptPPT
-
Nov 2016TranscriptPPT
-
Aug 2016TranscriptPPT
-
May 2016TranscriptPPT
-
Feb 2016TranscriptPPT
Parentage
The company is a subsidiary of Pfizer Inc. one of the world’s leading biopharma companies with a presence in over 125 countries. Pfizer develops and produces medicines and vaccines for immunology, oncology, cardiology, endocrinology, and neurology. [1] [2]